ArticleAdvances in radiation oncology2026
Trends in Intensity Modulated Radiation Therapy Utilization for Definitive Treatment of Intact Cervical Cancer, 2004-2019.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The objective of this study was to identify temporal trends in intensity modulated radiation therapy (IMRT) use for patients with cervical cancer who received definitive chemoradiation. Methods and Materials: Patients diagnosed with stage IB2-IVA cervical cancer between 2004 and 2019 and treated with definitive chemoradiation were identified in the National Cancer Database. The primary outcome of interest was the use of IMRT versus 3-dimensional conformal radiation therapy (3DCRT) over time. Wilcoxon rank-sum tests, chi-square tests, and multivariable logistic regression were used to identify factors associated with the receipt of IMRT. Results: Overall, 16,974 patients were included: 5388 (32%) received 3DCRT, and 11,586 (68%) received IMRT. IMRT use increased from 31% in 2004 to 75% in 2019 ( Conclusions: IMRT utilization for cervical cancer has increased over the last 15 years, especially for patients with advanced-stage disease or lymph node involvement. Understanding shifts in policy, demographic trends, and practice patterns may provide additional insight into the adoption of advanced technologies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.